Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis

Simos, Demetrios; Sajjady, Golmehr; Sergi, Melissa; Liew, Mun Sem; Califano, Raffaele; Ho, Cheryl; Leighl, Natasha B.; White, Shane; Summers, Yvonne; Wheatley‐Price, Paul

doi:10.1016/s0923-7534(20)34093-x

Cited by 14 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggested that the frequency of grade 3 or higher hematologic toxicities in our study were equivalent to the previous study. However, the frequency of febrile neutropenia was high (seven patients, 38.9%) compared with previous studies . In our study, the frequency of febrile neutropenia was higher for the starting dose of 40 mg/m 2 daily in 11 patients compared to that of ≤35 mg/m 2 daily in seven patients (63.6% vs. 0.0%; P = 0.002).…”

Section: Discussioncontrasting

confidence: 79%

“…The efficacy of third‐line treatment for SCLC has been previously reported in several studies. In an international analysis at five large cancer centers, the response rate and the time from third‐line chemotherapy until the time of death were 18% and 4.7 months, respectively . In the retrospective analysis of a US‐based community oncology electronic medical record, 334 patients were enrolled.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

et al. 2019

View full text Add to dashboard Cite

Background The efficacy of amrubicin for relapsed small‐cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third‐line amrubicin chemotherapy in patients with extensive disease (ED)‐SCLC. Methods We retrospectively analyzed the clinical records of ED‐SCLC patients treated with amrubicin salvage chemotherapy as a third‐line chemotherapy between January 2005 and July 2016 (salvage amrubicin group). The efficacy and toxicities of amrubicin were evaluated. Overall survival (OS) in the amrubicin salvage group was compared with OS among ED‐SCLC patients treated with at least second‐line chemotherapy between May 2000 and July 2016 and without subsequent amrubicin salvage chemotherapy. Results A total of 18 patients with a median age of 70 years were analyzed in the amrubicin salvage group. The median number of treatment cycles of amrubicin was four. The response rate was 27.8% (95% confidence interval (CI), 7.1%–48.5%), and the disease control rate (DCR) was 66.7% (95% CI, 44.9%–88.4%). Median progression‐free survival was 2.9 months (95% CI, 1.0–4.9 months), and median OS after an initial chemotherapy was 18.1 months (95% CI, 10.2–26.0 months). OS in the amrubicin salvage group was significantly longer than in the no‐amrubicin group (n = 19; 12.6 months, 95% CI, 11.5–13.8 months, P = 0.005). The frequency of neutropenia greater than grade 3 was 72.2%, with febrile neutropenia developing in 38.9% of patients in the amrubicin salvage group. Conclusions Despite a high frequency of febrile neutropenia, amrubicin salvage chemotherapy may improve OS in patients with relapsed ED‐SCLC.

show abstract

Section: Discussioncontrasting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The majority of patients with extensive-stage SCLC can only receive two lines of treatment (15). Although it has been shown that maintenance/consolidation CT may be useful to improve survival, the third-line and beyond lines treatments for SCLC are controversial (15,16).…”

Section: Discussionmentioning

confidence: 99%

The Clinical Features and Treatment Responses of Small Cell Lung Cancer Patients: A Single- Center Experience

Karaağaç

Yıldız²

2020

std

View full text Add to dashboard Cite

Amaç: Küçük hücreli akciğer kanseri (KHAK) agresif gidişatla ve kısa sağkalım süresi ile ilişkilidir. KHAK tedavisinin esasını konvansiyonel kemoterapi oluşturmaktadır. Bu çalışmamızda, KHAK' li hastaların güncel demografik ve klinik özelliklerinin tespit edilmesi ve uygulanan tedavilere alınan yanıtlarının belirlenmesi amaçlandı. Hastalar ve Yöntem: Bu bir retrospektif, kesitsel, kohort çalışmasıdır. Tedavi sonucunda radyolojik olarak tam yanıt (CR), kısmi yanıt (PR) ve stabil yanıt (SD) elde edilen hastalar ''yanıtlı'' olarak değerlendirilirken, hastalık ilerlemesi (PD) saptanan hastalar ''yanıtsız'' olarak değerlendirildi. Sağkalım tanımlamaları; tüm sağkalım süresinden (TOS) ve metastaz gelişiminden sonraki sağkalım süresinden (MOS) oluştu. TOS ile, KHAC' nin ilk saptandığı andan ölüme/sonvizite kadar geçen süre, MOS ile metastazının saptandığı andan ölüme/sonvizite kadar geçen süre ifade edildi. Bulgular: Çalışmada 161 hastanın verileri incelendi. 1. seri KT, 2.seri KT ve 3. seri KT ile elde edilen yanıt oranları sırasıyla %72.2, %43.3 ve %40.4 olarak belirlendi. Medyan TOS 15.7 ay (0.03-106.97), medyan MOS ise 13.79 (0.03-79.54) olarak hesaplandı. Hastaların medyan TOS değerini etkileyen univariate parametreler; kötü performans skoru, tanıda metastatik hastalık varlığı, tedaviyi reddetmek olarak belirlendi. Sonuç: Tedaviyi tolere edebilecek performansa sahip hastaların, hastalığın hangi sürecinde olursa olsun, tedavi çemberinde yer almalarının sağkalım avantajı ile neticelendiği gösterildi. .

show abstract

“…Response rates in second line treatments depend on the duration of disease control from the frontline treatment. Patients who relapse after three months have a response rate of 25% and also a rechallenge with the same platinum doublet can be offered (25), but that rate drops to 6% if the relapse occurs before this time point (26). Temozolamide demonstrated in a phase two study (27) a response rate of 38% in patients with brain metastasis, while other options in the second line setting are taxanes, gemcitabine, vinorlebine and irrinotecan (21).…”

Section: Current Treatment Standards For Small Cell Lung Cancermentioning

confidence: 99%

Perspectives in small cell lung cancer

Fotopoulos¹

2014

RIO

View full text Add to dashboard Cite

Third-Line Chemotherapy in Small Cell Lung Cancer: An International Analysis

Cited by 14 publications

References 0 publications

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

The Clinical Features and Treatment Responses of Small Cell Lung Cancer Patients: A Single- Center Experience

Perspectives in small cell lung cancer

Contact Info

Product

Resources

About